New biomarker analyses from the phase 3 CheckMate 77T trial provide critical insights into which patients with resectable non-small cell lung cancer (NSCLC) benefit most from perioperative immunotherapy with nivolumab (Opdivo). The data, presented at the European Society for Medical Oncology (ESMO) Congress 2024 and subsequently published, identify circulating tumor DNA (ctDNA) clearance as a pivotal early indicator of treatment success.
The trial demonstrated that the addition of perioperative nivolumab—given both before and after surgery—to chemotherapy significantly improved event-free survival (EFS) compared to neoadjuvant chemotherapy plus placebo. The new biomarker research shows that patients who achieved ctDNA clearance after neoadjuvant treatment (nivolumab plus chemotherapy) had markedly better outcomes. Their risk of disease recurrence, progression, or death was reduced by 88% compared to ctDNA-positive patients.
Further genomic analyses revealed that patients whose tumors had a high tumor mutational burden (TMB) or specific driver mutations (like KRAS G12C) also derived significant benefit from the nivolumab-based regimen. These findings move the field toward more personalized treatment strategies, where molecular features can help identify patients most likely to achieve a pathologic complete response and long-term survival with perioperative immunotherapy.
The CheckMate 77T results solidify the role of perioperative nivolumab in resectable NSCLC and underscore the importance of ctDNA as a dynamic, non-invasive tool for monitoring treatment response and guiding prognosis. Ongoing research focuses on integrating these biomarkers into clinical practice to optimize patient selection.
